Theraclion refines its strategy – Capital.fr

(AOF) – Theraclion has reiterated its strategy in three therapeutic areas. At the beginning of the year, biotech’s ambition to replace the surgical procedure with a robotic platform for non-invasive treatment with echotherapy is coming to fruition. Theraclion’s growth strategy is to expand into three major therapeutic areas in three geographies: varicose veins, in the United States (seeking FDA clearance) and in Europe; thyroid, in Europe and China; breast cancer, mainly in the United States and through strategic partnerships.

In 2021, Theraclion mainly expanded into the varicose veins market, where the SONOVEIN device has proven its effectiveness. SONOVEIN has recently expanded into new markets and is now available to the leading opinion leaders in vascular surgery in all major European markets. In addition, Theraclion is also redeveloping in the thyroid cancer and breast cancer markets with ECHOPULSE.

The focus is on early-stage breast cancer following the promising results of an initial study in collaboration with the University of Virginia Cancer Center (USA) in research on the treatment of breast cancer using the HIFU system.

After a successful first collaboration on patients with advanced breast cancer, the University of Virginia (UVA) cancer Center has begun using Theraclion’s world-class technology in an early-stage breast cancer study.

–

©
AOF

Legal warning

The AOF information reproduced on Capital.fr are extracted from the AOF information service.
This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors.
Consequently, any reproduction, copy, duplication, modification, transfer, rebroadcast, translation, commercial or non-commercial exploitation, creation of hypertext links or reuse in any way of this information is subject to the prior written consent of OPTION FINANCE SAS and its contributors.
AOF can be reached at the following address [email protected]
OPTION FINANCE SAS collects its data from the sources it considers the most secure. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not guarantee the absence of errors and defects, even hidden, nor the completeness or lack of conformity to any use of these data and OPTION FINANCE SAS or one of its contributors, and can not be held responsible for delays or interruptions that could affect access to the latter.
The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

–